最近结合性组织疾病的发展与肺动脉高血压相关
Stefano Rodolfi1,2,3, Voon H Ong1, Christopher P Denton1
1Centre for Rheumatology and Connective Tissue Diseases, University College London Medical School, London, UK.
International journal of cardiology. Congenital heart disease
|December 23, 2024
概括
连接组织疾病相关的肺动脉高血压 (CTD-PAH) 管理随着临床试验的纳入而得到改善. 在CTD早期检测提供优势比异常性PAH,虽然复杂的并发症提出挑战.
科学领域:
- 心脏病学 心脏病学
- 类风湿病学 类风湿病学
- 肺部病理学 肺部病理学
背景情况:
- 连接组织疾病相关的肺动脉高血压 (CTD-PAH) 已经在治疗方面取得了进展.
- 关键临床试验改善了CTD-PAH的药物可用性和患者结果.
研究的目的:
- 审查最近在CTD-PAH的调查和管理方面的进展.
- 突出管理CTD-PAH的挑战和机遇.
主要方法:
- 关于CTD-PAH的最新文献的审查.
- 分析临床试验数据和管理策略.
主要成果:
- CTD-PAH结果有所改善,但面临着伴随疾病带来的挑战.
- 系统性硬化症相关的PAH通常比异常性PAH的生存率更差.
- CTD为PAH的早期查和检测提供了潜力.
结论:
- 尽管存在挑战,但CTD-PAH管理从研究和临床试验中受益.
- 在CTD患者中早期检测可能会改善长期预后.
- 需要进一步的研究来解决复杂的表型和并发症.
相关概念视频
Pulmonary Hypertension: Classification and Pathogenesis
150
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
150
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
140
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
140
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
171
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
171
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
147
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
147
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.7K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.7K
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
2.7K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
2.7K


